Clinical Trial Update: Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tPA for atypical ARDS in COVID-19 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• tPA (tissue plasminogen activator)

Snippet

Sponsor: Negovsky Reanimatology Research Institute | Conditions: Acute Respiratory Distress Syndrome | Phase 3 | Status: WITHDRAWN